Navigation Links
HeartWare to Present at the UBS Global Life Sciences Conference
Date:9/14/2011

FRAMINGHAM, Mass. and SYDNEY, Sept. 14, 2011 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the UBS Global Life Sciences Conference at 10:30 a.m. ET on Wednesday, September 21, 2011.  The conference is being held September 19-21, 2011 at the Grand Hyatt in New York City.

A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com.  A replay of the webcast will be available at the site after the presentation.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® Pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union and TGA approval in Australia.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant and destination therapy.  For additional information, please visit www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

HEARTWARE, HVAD, MVAD and HeartWare logos are registered trad
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. HeartWare Completes GLP Studies of Next Generation MVAD® Pump; Data Presented Today at ISRBP Congress
2. HeartWare to Report 2010 Fourth Quarter and Year-End Financial Results
3. HeartWare to Present at the 22nd Annual Piper Jaffray Health Care Conference
4. HeartWare International, Inc. Temporary Suspension of Trading
5. U.S. Federal Trade Commission to Challenge Thoratecs Proposed Acquisition of HeartWare International
6. Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference
7. Tengion to Present at UBS Global Life Sciences Conference
8. Healthpoint Biotherapeutics to Present at UBS Global Life Sciences Conference
9. Saladax Biomedical, Inc. to Present at the Annual UBS Global Life Sciences Conference in New York City
10. Metabolic Solutions Development Company Presents New Brown Fat Research at the European Association for the Study of Diabetes
11. Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... -- Research and Markets has announced the addition ... report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... used to determine the size of a particle in a ... analyze the size of particles as it can affect the ... to determine the behavior and nature of a material, and ...
(Date:7/26/2014)... Canada Endoscopy Visualization Systems Market ... the Canada Endoscopy Visualization Systems market. The report ... (in units) and average prices (in US dollars) ... Mid-Range Endoscopy Visualization Systems and Low-End Endoscopy Visualization ... . , The report also provides company shares ...
(Date:7/25/2014)... , July 25, 2014 Amgen (NASDAQ: ... Directors today declared a $0.61 per share dividend for ... paid on Sept. 5, 2014, to all stockholders of ... 14, 2014.  About Amgen Amgen is ... suffering from serious illnesses by discovering, developing, manufacturing and ...
(Date:7/25/2014)... new study by researchers from the University of ... nanosystems function, unlocking the potential to create new ... which has been published in the prestigious academic ... novel laser technique to examine in rich detail ... small cluster containing an acetylene molecule and a ...
Breaking Biology Technology:Global Particle Size Analysis Market 2014-2018 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3
... SAN DIEGO, Aug. 25 NexBio, Inc. announced today ... Human Lung Tissues" in the September, 2009 issue of the ... DAS181 (Fludase ((R)) ) is an investigational drug ... (e.g. Tamiflu ((R)) ), which target the virus, DAS181 works ...
... 25 Peptimmune, Inc., a privately held biotechnology company, ... the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in ... is a novel peptide copolymer for the treatment of ... The Phase Ib multiple-ascending dose, double-blind, placebo-controlled, ...
... - Medicago Inc. (TSX-V: MDG) a biotechnology company ... based on proprietary manufacturing technologies and Virus-Like Particles ... from Health Canada to commence a Phase I ... vaccine ("H5N1 vaccine"). Enrollment of volunteers is now ...
Cached Biology Technology:NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue 2NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue 3NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue 4Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 2Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 3Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine 2Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine 3
(Date:7/27/2014)... date, researchers from the U.K. provide national, regional, and ... (HCV). Findings published in Hepatology, a journal of the ... that genotype 1 is the most prevalent worldwide, with ... in East Asia. Genotype 3, at just over 54 ... genotypes 2, 4, 6, and 5. , Despite ...
(Date:7/27/2014)... Microorganisms like bacteria and fungi can evade treatment by ... antifungal drugs. These permanent mutations were once thought to ... Now a new study has shown that microorganisms can ... as epimutations -- to gain the benefits of drug ... was discovered in a fungus called Mucor circinelloides, it ...
(Date:7/27/2014)... have found that targeting a molecule in blood vessels ... research published in Nature today (Sunday)., The ... University of London, have found that a molecule, called ... itself after chemotherapy or radiotherapy, which kill cancer cells ... blood vessels that grew in melanoma or lung cancer ...
Breaking Biology News(10 mins):Hepatitis C virus genotype 1 is most prevalent worldwide 2Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3New drug target can break down cancer's barrier against treatment 2
... the Pediatric Study of Hepatitis C (PEDS-C) trial reveals ... C (HCV) display significant changes in height, weight, body ... the August issue of Hepatology , a journal ... Diseases, indicate that most growth-related side effects are reversible ...
... Clemson University researchers are teaming up with Coastal ... of sensors along the Savannah River to gather data ... will collect and transmit real-time information about the quality ... Intelligent River project leaders Gene Eidson, director of Clemson,s ...
... Lab on a chip (LOC) devicesmicrochip-size systems that can ... from a few microliters (millionth of a liter) to ... to one day revolutionize how laboratory tasks such as ... a recent paper* from the National Institute of Standards ...
Cached Biology News:Height, weight and BMI changes seen in children treated with peginterferon alpha for hepatitis C 2Clemson, Coastal Carolina universities to set hundreds of sensors in Savannah River 2NIST focuses on testing standards to support lab on a chip commercialization 2
...
Hygromycin resistance gene (hph), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
... provides a simple and efficient means for ... lture using annexin V magnetic beads (MagBeads). ... protein with high affinity for phosphatidylseri ... simple and efficient means for isolation of ...
... Linkage: This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
Biology Products: